There are indeed many questionable COVID-19 antibody tests currently available in the US market. The FDA recently launched a national investigation of antibody testing manufacturers and is now requiring them to submit clinical testing data and receive an Emergency Use Authorization (EUA). The EUA process requires testing manufacturers to meet the sensitivity and specificity standards established by the FDA to ensure these tests' quality.
ZOOM+Care partners with a national reference lab, LabCorp, to support all of the COVID-19 testing conducted at our clinics. We are continually monitoring this testing platform to ensure our partners meet our rigorous quality standards and the expectations of our patients, clinicians, and the communities we serve.
LabCorp will bill your insurance directly. The cost of this antibody panel is $50. While most insurance providers will cover the cost, we encourage patients to check with their insurer prior to scheduling their test.
All persons are eligible for antibody testing unless they are:
Our doctors can determine if you are eligible for antibody testing. However, in order to receive testing, you must be symptom-free for at least ten days.
Typically, results from antibody tests are available within 3-5 days.
It is important to recognize that all COVID-19 tests approved through the EUA process were validated in relatively small patient populations when compared to traditional testing standards. Current EUA approval requires all antibody tests to accurately identify at least 90% of positive cases (sensitivity) and 95% of negative cases (specificity). Estimates of sensitivity and specificity are just that, estimates. They include 95% confidence intervals, which are the range of estimates we are about 95% sure a test's sensitivity and specificity will fall within, given how many samples were used in the performance validation. The more samples used to validate a test, the smaller the confidence interval becomes, meaning that we can be more confident in the estimates of sensitivity and specificity provided.
LabCorp uses the Abbott Architect as the primary testing platform to detect IgG antibodies to the COVID-19 virus.
Coronaviruses are composed of several proteins, including the spike, envelope, membrane, and nucleocapsid proteins. A set of assay platforms are used to detect antibodies to COVID-19. These are designed to detect antibodies binding to the recombinant S1 domain of SARS-CoV-2 spike protein and the nucleocapsid protein.
Currently, ZOOM+Care is licensed to mail prescriptions within Oregon and Washington.